ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

POAI Predictive Oncology Inc

1.57
-0.08 (-4.85%)
Pre Market
Last Updated: 10:42:18
Delayed by 15 minutes
Share Name Share Symbol Market Type
Predictive Oncology Inc NASDAQ:POAI NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.08 -4.85% 1.57 1.56 1.61 6,242 10:42:18

Predictive Oncology Hires Investor Relations Firm

05/01/2021 1:30pm

GlobeNewswire Inc.


Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Predictive Oncology Charts.

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is pleased to announce that it has engaged Landon Capital to provide investor relations services effective December 30, 2020.  Services will include introductions to investors, financial and industry analysts, registered brokers and financial writers with a view to informing such groups about developments in the Company’s business and affairs. Landon Capital will assist to develop a database of individuals, financial institutions or other persons potentially interested in receiving publicly available information relating to the Company and making efforts to efficiently provide such information.

About Predictive Oncology Inc.

Predictive Oncology (NASDAQ: POAI) operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech.

Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement, and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins, and protein complexes.

Forward-Looking Statements

Certain matters discussed in this release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,” “target” and similar expressions are intended to identify forward- looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading “Risk Factors” in our filings with the SEC. Except as expressly required by law, the Company disclaims any intent or obligation to update these forward-looking statements.

Investor Relations Contact:

Landon Capital Keith Pinder (404) 995-667kpinder@landoncapital.net

 

1 Year Predictive Oncology Chart

1 Year Predictive Oncology Chart

1 Month Predictive Oncology Chart

1 Month Predictive Oncology Chart

Your Recent History

Delayed Upgrade Clock